Pulse Biosciences, Inc. cash flow to debt ratio of -718.75% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Pulse Biosciences, Inc.'s free cash flow has decreased 49.27% from $-36.47M last year to $-54.44M, signaling decreasing performance

Pulse Biosciences, Inc.'s debt to equity ratio is 0.07, which means that the company's assets are healthy financed, signaling financial stability.

Pulse Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.08 last year to 0.07 today, signaling strengthened financials

Pulse Biosciences, Inc. has a net cash position, so leverage is healthy.

Pulse Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Pulse Biosciences, Inc. has insufficient data to evaluate this check.

Pulse Biosciences, Inc.'s short-term assets of $83.42M exceed its short-term liabilities of $7.92M

Pulse Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pulse Biosciences, Inc.'s return on equity of -94.42%, is lower than 15.00%, indicating bad performance

Pulse Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Pulse Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Pulse Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Pulse Biosciences, Inc. has negative free cash flow, indicating cash burn

Pulse Biosciences, Inc.'s yearly earnings has decreased 35.82% since last year from $-53.59M to $-72.78M, signaling decreasing performance

Pulse Biosciences, Inc.'s yearly revenue has increased % since last year from $0.00 to $350.00K, signaling increasing performance

ROIC -78.14% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Pulse Biosciences, Inc.'s 3-year revenue CAGR of -20.63% is negative, indicating declining revenue over the past 3 years

Pulse Biosciences, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Pulse Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Pulse Biosciences, Inc. has insufficient data to evaluate this check.

Pulse Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pulse Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Pulse Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Pulse Biosciences, Inc. has insufficient data to evaluate this check.

Pulse Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pulse Biosciences, Inc. has a price-to-book ratio of 28.87x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Pulse Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue